JP2013507442A - 組合せ - Google Patents

組合せ Download PDF

Info

Publication number: JP2013507442A
Authority: JP; Japan
Prior art keywords: compound; cancer; pharmaceutically acceptable; acceptable salt; human
Prior art date: 2009-10-12
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Ceased

Application number

JP2012534272A

Other languages

English (en)

Japanese (ja)

Other versions

JP2013507442A5 (2

Inventor

クルト、オージェ

カーティス、アール、バックマン

ジョエル、デイビッド、グレショック

トナ、ギルマー

シルビー、ラケル

シャノン、レネ、モリス

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

GlaxoSmithKline LLC

Original Assignee

GlaxoSmithKline LLC

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2009-10-12

Filing date

2010-10-12

Publication date

2013-03-04

2010-10-12 Application filed by GlaxoSmithKline LLC filed Critical GlaxoSmithKline LLC

2013-03-04 Publication of JP2013507442A publication Critical patent/JP2013507442A/ja

2013-10-24 Publication of JP2013507442A5 publication Critical patent/JP2013507442A5/ja

Status Ceased legal-status Critical Current

Links

150000003839 salts Chemical class 0.000 claims abstract description 79
206010028980 Neoplasm Diseases 0.000 claims abstract description 68
238000000034 method Methods 0.000 claims abstract description 59
201000011510 cancer Diseases 0.000 claims abstract description 58
238000011282 treatment Methods 0.000 claims abstract description 46
239000012453 solvate Substances 0.000 claims abstract description 40
-1 2-fluoro-4-iodo-phenylamino Chemical group 0.000 claims abstract description 19
239000008194 pharmaceutical composition Substances 0.000 claims abstract description 19
CGBJSGAELGCMKE-UHFFFAOYSA-N omipalisib Chemical compound COC1=NC=C(C=2C=C3C(C=4C=NN=CC=4)=CC=NC3=CC=2)C=C1NS(=O)(=O)C1=CC=C(F)C=C1F CGBJSGAELGCMKE-UHFFFAOYSA-N 0.000 claims abstract description 14
150000001875 compounds Chemical class 0.000 claims description 192
239000003814 drug Substances 0.000 claims description 48
125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 16
206010009944 Colon cancer Diseases 0.000 claims description 14
239000003937 drug carrier Substances 0.000 claims description 13
125000004940 pyridazin-4-yl group Chemical group N1=NC=C(C=C1)* 0.000 claims description 13
208000029742 colonic neoplasm Diseases 0.000 claims description 12
201000001441 melanoma Diseases 0.000 claims description 12
GRVDJDISBSALJP-UHFFFAOYSA-N methyloxidanyl Chemical group [O]C GRVDJDISBSALJP-UHFFFAOYSA-N 0.000 claims description 12
229940125431 BRAF inhibitor Drugs 0.000 claims description 10
101000984753 Homo sapiens Serine/threonine-protein kinase B-raf Proteins 0.000 claims description 9
102100027103 Serine/threonine-protein kinase B-raf Human genes 0.000 claims description 9
BFSMGDJOXZAERB-UHFFFAOYSA-N dabrafenib Chemical compound S1C(C(C)(C)C)=NC(C=2C(=C(NS(=O)(=O)C=3C(=CC=CC=3F)F)C=CC=2)F)=C1C1=CC=NC(N)=N1 BFSMGDJOXZAERB-UHFFFAOYSA-N 0.000 claims description 8
206010006187 Breast cancer Diseases 0.000 claims description 5
208000026310 Breast neoplasm Diseases 0.000 claims description 5
206010058467 Lung neoplasm malignant Diseases 0.000 claims description 5
206010061902 Pancreatic neoplasm Diseases 0.000 claims description 5
238000001727 in vivo Methods 0.000 claims description 5
201000005202 lung cancer Diseases 0.000 claims description 5
208000020816 lung neoplasm Diseases 0.000 claims description 5
208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 5
201000002528 pancreatic cancer Diseases 0.000 claims description 5
208000008443 pancreatic carcinoma Diseases 0.000 claims description 5
239000012458 free base Substances 0.000 claims description 3
238000004519 manufacturing process Methods 0.000 claims description 3
238000002560 therapeutic procedure Methods 0.000 claims description 3
AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 claims description 2
125000001207 fluorophenyl group Chemical group 0.000 claims 4
VPALIXSHVAOPHS-UHFFFAOYSA-N C1=CC=C(C=C1)S(=O)(=O)NC(F)(F)S(=O)(=O)O Chemical compound C1=CC=C(C=C1)S(=O)(=O)NC(F)(F)S(=O)(=O)O VPALIXSHVAOPHS-UHFFFAOYSA-N 0.000 claims 3
101000958041 Homo sapiens Musculin Proteins 0.000 claims 3
102000046949 human MSC Human genes 0.000 claims 3
DWBWMAAYLWUXQK-UHFFFAOYSA-N 2,3-difluorobenzenesulfonamide Chemical compound NS(=O)(=O)C1=CC=CC(F)=C1F DWBWMAAYLWUXQK-UHFFFAOYSA-N 0.000 claims 2
ZFULUTKKGBUXHC-UHFFFAOYSA-N 2,3-difluorobenzenesulfonamide;methanesulfonic acid Chemical compound CS(O)(=O)=O.NS(=O)(=O)C1=CC=CC(F)=C1F ZFULUTKKGBUXHC-UHFFFAOYSA-N 0.000 claims 1
KHBQMWCZKVMBLN-UHFFFAOYSA-N Benzenesulfonamide Chemical compound NS(=O)(=O)C1=CC=CC=C1 KHBQMWCZKVMBLN-UHFFFAOYSA-N 0.000 claims 1
YKGMKSIHIVVYKY-UHFFFAOYSA-N dabrafenib mesylate Chemical compound CS(O)(=O)=O.S1C(C(C)(C)C)=NC(C=2C(=C(NS(=O)(=O)C=3C(=CC=CC=3F)F)C=CC=2)F)=C1C1=CC=NC(N)=N1 YKGMKSIHIVVYKY-UHFFFAOYSA-N 0.000 claims 1
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
239000003795 chemical substances by application Substances 0.000 abstract description 21
239000003112 inhibitor Substances 0.000 abstract description 6
241000124008 Mammalia Species 0.000 abstract description 2
229940124647 MEK inhibitor Drugs 0.000 abstract 1
229940116355 PI3 kinase inhibitor Drugs 0.000 abstract 1
METKIMKYRPQLGS-UHFFFAOYSA-N atenolol Chemical compound CC(C)NCC(O)COC1=CC=C(CC(N)=O)C=C1 METKIMKYRPQLGS-UHFFFAOYSA-N 0.000 abstract 1
239000002829 mitogen activated protein kinase inhibitor Substances 0.000 abstract 1
239000002935 phosphatidylinositol 3 kinase inhibitor Substances 0.000 abstract 1
210000004027 cell Anatomy 0.000 description 95
229940126062 Compound A Drugs 0.000 description 79
NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 description 79
229940079593 drug Drugs 0.000 description 43
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 28
108091007960 PI3Ks Proteins 0.000 description 22
108090000430 Phosphatidylinositol 3-kinases Proteins 0.000 description 22
102000003993 Phosphatidylinositol 3-kinases Human genes 0.000 description 22
230000000694 effects Effects 0.000 description 19
230000035772 mutation Effects 0.000 description 18
230000002195 synergetic effect Effects 0.000 description 18
230000037361 pathway Effects 0.000 description 15
108091000080 Phosphotransferase Proteins 0.000 description 14
102000020233 phosphotransferase Human genes 0.000 description 14
230000010261 cell growth Effects 0.000 description 12
238000010790 dilution Methods 0.000 description 12
239000012895 dilution Substances 0.000 description 12
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 12
230000005764 inhibitory process Effects 0.000 description 11
201000010099 disease Diseases 0.000 description 10
239000000203 mixture Substances 0.000 description 10
108090000623 proteins and genes Proteins 0.000 description 10
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 9
108010011536 PTEN Phosphohydrolase Proteins 0.000 description 9
102000001253 Protein Kinase Human genes 0.000 description 9
239000000890 drug combination Substances 0.000 description 9
108060006633 protein kinase Proteins 0.000 description 9
238000012360 testing method Methods 0.000 description 9
239000012828 PI3K inhibitor Substances 0.000 description 8
102000014160 PTEN Phosphohydrolase Human genes 0.000 description 8
238000006243 chemical reaction Methods 0.000 description 8
229940043441 phosphoinositide 3-kinase inhibitor Drugs 0.000 description 8
230000004044 response Effects 0.000 description 8
239000002904 solvent Substances 0.000 description 8
108091003079 Bovine Serum Albumin Proteins 0.000 description 7
230000000996 additive effect Effects 0.000 description 7
238000012054 celltiter-glo Methods 0.000 description 7
238000009472 formulation Methods 0.000 description 7
230000012010 growth Effects 0.000 description 7
235000018102 proteins Nutrition 0.000 description 7
102000004169 proteins and genes Human genes 0.000 description 7
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
102000004190 Enzymes Human genes 0.000 description 6
108090000790 Enzymes Proteins 0.000 description 6
239000000654 additive Substances 0.000 description 6
230000002301 combined effect Effects 0.000 description 6
239000012091 fetal bovine serum Substances 0.000 description 6
238000005259 measurement Methods 0.000 description 6
206010033128 Ovarian cancer Diseases 0.000 description 5
206010061535 Ovarian neoplasm Diseases 0.000 description 5
102100038332 Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform Human genes 0.000 description 5
102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 5
108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 5
229920002472 Starch Polymers 0.000 description 5
108010065917 TOR Serine-Threonine Kinases Proteins 0.000 description 5
102000013530 TOR Serine-Threonine Kinases Human genes 0.000 description 5
230000006907 apoptotic process Effects 0.000 description 5
238000003556 assay Methods 0.000 description 5
230000004663 cell proliferation Effects 0.000 description 5
238000002474 experimental method Methods 0.000 description 5
239000004615 ingredient Substances 0.000 description 5
230000002401 inhibitory effect Effects 0.000 description 5
239000002609 medium Substances 0.000 description 5
230000001105 regulatory effect Effects 0.000 description 5
239000000243 solution Substances 0.000 description 5
239000008107 starch Substances 0.000 description 5
235000019698 starch Nutrition 0.000 description 5
230000001225 therapeutic effect Effects 0.000 description 5
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
KKVYYGGCHJGEFJ-UHFFFAOYSA-N 1-n-(4-chlorophenyl)-6-methyl-5-n-[3-(7h-purin-6-yl)pyridin-2-yl]isoquinoline-1,5-diamine Chemical compound N=1C=CC2=C(NC=3C(=CC=CN=3)C=3C=4N=CNC=4N=CN=3)C(C)=CC=C2C=1NC1=CC=C(Cl)C=C1 KKVYYGGCHJGEFJ-UHFFFAOYSA-N 0.000 description 4
108010010803 Gelatin Proteins 0.000 description 4
101000605639 Homo sapiens Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform Proteins 0.000 description 4
101001059454 Homo sapiens Serine/threonine-protein kinase MARK2 Proteins 0.000 description 4
108091054455 MAP kinase family Proteins 0.000 description 4
102000043136 MAP kinase family Human genes 0.000 description 4
101100381978 Mus musculus Braf gene Proteins 0.000 description 4
102100028904 Serine/threonine-protein kinase MARK2 Human genes 0.000 description 4
235000021355 Stearic acid Nutrition 0.000 description 4
229930006000 Sucrose Natural products 0.000 description 4
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 4
230000003042 antagnostic effect Effects 0.000 description 4
230000003831 deregulation Effects 0.000 description 4
239000002552 dosage form Substances 0.000 description 4
239000008273 gelatin Substances 0.000 description 4
229920000159 gelatin Polymers 0.000 description 4
239000007903 gelatin capsule Substances 0.000 description 4
235000019322 gelatine Nutrition 0.000 description 4
235000011852 gelatine desserts Nutrition 0.000 description 4
208000005017 glioblastoma Diseases 0.000 description 4
208000032839 leukemia Diseases 0.000 description 4
QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 4
OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 4
229920001184 polypeptide Polymers 0.000 description 4
102000004196 processed proteins & peptides Human genes 0.000 description 4
108090000765 processed proteins & peptides Proteins 0.000 description 4
230000019491 signal transduction Effects 0.000 description 4
239000008117 stearic acid Substances 0.000 description 4
UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 4
239000005720 sucrose Substances 0.000 description 4
239000000454 talc Substances 0.000 description 4
235000012222 talc Nutrition 0.000 description 4
229910052623 talc Inorganic materials 0.000 description 4
210000004881 tumor cell Anatomy 0.000 description 4
SFHYNDMGZXWXBU-LIMNOBDPSA-N 6-amino-2-[[(e)-(3-formylphenyl)methylideneamino]carbamoylamino]-1,3-dioxobenzo[de]isoquinoline-5,8-disulfonic acid Chemical compound O=C1C(C2=3)=CC(S(O)(=O)=O)=CC=3C(N)=C(S(O)(=O)=O)C=C2C(=O)N1NC(=O)N\N=C\C1=CC=CC(C=O)=C1 SFHYNDMGZXWXBU-LIMNOBDPSA-N 0.000 description 3
208000005623 Carcinogenesis Diseases 0.000 description 3
230000004544 DNA amplification Effects 0.000 description 3
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
229920000168 Microcrystalline cellulose Polymers 0.000 description 3
206010060862 Prostate cancer Diseases 0.000 description 3
208000000236 Prostatic Neoplasms Diseases 0.000 description 3
230000002159 abnormal effect Effects 0.000 description 3
230000003213 activating effect Effects 0.000 description 3
230000004913 activation Effects 0.000 description 3
239000004480 active ingredient Substances 0.000 description 3
125000003275 alpha amino acid group Chemical group 0.000 description 3
238000004458 analytical method Methods 0.000 description 3
238000003705 background correction Methods 0.000 description 3
238000004364 calculation method Methods 0.000 description 3
230000036952 cancer formation Effects 0.000 description 3
239000007963 capsule composition Substances 0.000 description 3
231100000504 carcinogenesis Toxicity 0.000 description 3
239000000969 carrier Substances 0.000 description 3
230000030833 cell death Effects 0.000 description 3
239000003153 chemical reaction reagent Substances 0.000 description 3
238000007405 data analysis Methods 0.000 description 3
230000007423 decrease Effects 0.000 description 3
238000011049 filling Methods 0.000 description 3
230000006870 function Effects 0.000 description 3
239000008187 granular material Substances 0.000 description 3
230000009036 growth inhibition Effects 0.000 description 3
238000000338 in vitro Methods 0.000 description 3
239000007788 liquid Substances 0.000 description 3
238000011068 loading method Methods 0.000 description 3
238000004020 luminiscence type Methods 0.000 description 3
235000019813 microcrystalline cellulose Nutrition 0.000 description 3
239000008108 microcrystalline cellulose Substances 0.000 description 3
229940016286 microcrystalline cellulose Drugs 0.000 description 3
238000010899 nucleation Methods 0.000 description 3
108020004707 nucleic acids Proteins 0.000 description 3
102000039446 nucleic acids Human genes 0.000 description 3
150000007523 nucleic acids Chemical class 0.000 description 3
239000006186 oral dosage form Substances 0.000 description 3
230000026731 phosphorylation Effects 0.000 description 3
238000006366 phosphorylation reaction Methods 0.000 description 3
102000040430 polynucleotide Human genes 0.000 description 3
108091033319 polynucleotide Proteins 0.000 description 3
239000002157 polynucleotide Substances 0.000 description 3
230000002265 prevention Effects 0.000 description 3
230000008569 process Effects 0.000 description 3
230000035755 proliferation Effects 0.000 description 3
230000002829 reductive effect Effects 0.000 description 3
239000007787 solid Substances 0.000 description 3
239000000758 substrate Substances 0.000 description 3
239000003826 tablet Substances 0.000 description 3
239000007916 tablet composition Substances 0.000 description 3
210000001519 tissue Anatomy 0.000 description 3
VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
IZHVBANLECCAGF-UHFFFAOYSA-N 2-hydroxy-3-(octadecanoyloxy)propyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)COC(=O)CCCCCCCCCCCCCCCCC IZHVBANLECCAGF-UHFFFAOYSA-N 0.000 description 2
208000003174 Brain Neoplasms Diseases 0.000 description 2
208000001333 Colorectal Neoplasms Diseases 0.000 description 2
208000012609 Cowden disease Diseases 0.000 description 2
102100030708 GTPase KRas Human genes 0.000 description 2
206010051066 Gastrointestinal stromal tumour Diseases 0.000 description 2
208000032612 Glial tumor Diseases 0.000 description 2
206010018338 Glioma Diseases 0.000 description 2
101000584612 Homo sapiens GTPase KRas Proteins 0.000 description 2
101001120056 Homo sapiens Phosphatidylinositol 3-kinase regulatory subunit alpha Proteins 0.000 description 2
206010025323 Lymphomas Diseases 0.000 description 2
208000008770 Multiple Hamartoma Syndrome Diseases 0.000 description 2
208000034578 Multiple myelomas Diseases 0.000 description 2
108700020796 Oncogene Proteins 0.000 description 2
102000043276 Oncogene Human genes 0.000 description 2
229930182555 Penicillin Natural products 0.000 description 2
JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 2
102100026169 Phosphatidylinositol 3-kinase regulatory subunit alpha Human genes 0.000 description 2
206010035226 Plasma cell myeloma Diseases 0.000 description 2
239000012979 RPMI medium Substances 0.000 description 2
239000012980 RPMI-1640 medium Substances 0.000 description 2
208000000389 T-cell leukemia Diseases 0.000 description 2
208000028530 T-cell lymphoblastic leukemia/lymphoma Diseases 0.000 description 2
208000024770 Thyroid neoplasm Diseases 0.000 description 2
230000008485 antagonism Effects 0.000 description 2
230000001093 anti-cancer Effects 0.000 description 2
230000009286 beneficial effect Effects 0.000 description 2
230000008901 benefit Effects 0.000 description 2
230000033228 biological regulation Effects 0.000 description 2
239000000090 biomarker Substances 0.000 description 2
239000002775 capsule Substances 0.000 description 2
239000006143 cell culture medium Substances 0.000 description 2
230000032823 cell division Effects 0.000 description 2
238000001516 cell proliferation assay Methods 0.000 description 2
229940000425 combination drug Drugs 0.000 description 2
238000011284 combination treatment Methods 0.000 description 2
210000000805 cytoplasm Anatomy 0.000 description 2
208000035475 disorder Diseases 0.000 description 2
231100000673 dose–response relationship Toxicity 0.000 description 2
239000000796 flavoring agent Substances 0.000 description 2
235000013355 food flavoring agent Nutrition 0.000 description 2
201000011243 gastrointestinal stromal tumor Diseases 0.000 description 2
230000002068 genetic effect Effects 0.000 description 2
201000010536 head and neck cancer Diseases 0.000 description 2
208000014829 head and neck neoplasm Diseases 0.000 description 2
210000003734 kidney Anatomy 0.000 description 2
201000007270 liver cancer Diseases 0.000 description 2
208000014018 liver neoplasm Diseases 0.000 description 2
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
238000012423 maintenance Methods 0.000 description 2
239000011159 matrix material Substances 0.000 description 2
230000007246 mechanism Effects 0.000 description 2
238000002156 mixing Methods 0.000 description 2
230000004048 modification Effects 0.000 description 2
238000012986 modification Methods 0.000 description 2
239000001788 mono and diglycerides of fatty acids Substances 0.000 description 2
238000011275 oncology therapy Methods 0.000 description 2
229940049954 penicillin Drugs 0.000 description 2
150000003905 phosphatidylinositols Chemical class 0.000 description 2
230000003389 potentiating effect Effects 0.000 description 2
238000002360 preparation method Methods 0.000 description 2
239000000651 prodrug Substances 0.000 description 2
229940002612 prodrug Drugs 0.000 description 2
230000002062 proliferating effect Effects 0.000 description 2
238000011321 prophylaxis Methods 0.000 description 2
238000004445 quantitative analysis Methods 0.000 description 2
108010077182 raf Kinases Proteins 0.000 description 2
102000009929 raf Kinases Human genes 0.000 description 2
102000005962 receptors Human genes 0.000 description 2
108020003175 receptors Proteins 0.000 description 2
238000011160 research Methods 0.000 description 2
102200055464 rs113488022 Human genes 0.000 description 2
238000012216 screening Methods 0.000 description 2
DAEPDZWVDSPTHF-UHFFFAOYSA-M sodium pyruvate Chemical compound [Na+].CC(=O)C([O-])=O DAEPDZWVDSPTHF-UHFFFAOYSA-M 0.000 description 2
229960005322 streptomycin Drugs 0.000 description 2
230000004083 survival effect Effects 0.000 description 2
208000011580 syndromic disease Diseases 0.000 description 2
239000006188 syrup Substances 0.000 description 2
235000020357 syrup Nutrition 0.000 description 2
201000002510 thyroid cancer Diseases 0.000 description 2
238000013519 translation Methods 0.000 description 2
125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 2
MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
102100037263 3-phosphoinositide-dependent protein kinase 1 Human genes 0.000 description 1
206010069754 Acquired gene mutation Diseases 0.000 description 1
206010000830 Acute leukaemia Diseases 0.000 description 1
208000024893 Acute lymphoblastic leukemia Diseases 0.000 description 1
208000014697 Acute lymphocytic leukaemia Diseases 0.000 description 1
208000031261 Acute myeloid leukaemia Diseases 0.000 description 1
229920001817 Agar Polymers 0.000 description 1
230000007730 Akt signaling Effects 0.000 description 1
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
206010003571 Astrocytoma Diseases 0.000 description 1
208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 description 1
208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 1
206010005003 Bladder cancer Diseases 0.000 description 1
206010005969 Bone giant cell tumour Diseases 0.000 description 1
206010065687 Bone loss Diseases 0.000 description 1
208000011691 Burkitt lymphomas Diseases 0.000 description 1
WSNMPAVSZJSIMT-UHFFFAOYSA-N COc1c(C)c2COC(=O)c2c(O)c1CC(O)C1(C)CCC(=O)O1 Chemical compound COc1c(C)c2COC(=O)c2c(O)c1CC(O)C1(C)CCC(=O)O1 WSNMPAVSZJSIMT-UHFFFAOYSA-N 0.000 description 1
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
108010026870 Calcium-Calmodulin-Dependent Protein Kinases Proteins 0.000 description 1
102000019025 Calcium-Calmodulin-Dependent Protein Kinases Human genes 0.000 description 1
208000024172 Cardiovascular disease Diseases 0.000 description 1
108010031425 Casein Kinases Proteins 0.000 description 1
102000005403 Casein Kinases Human genes 0.000 description 1
102000011068 Cdc42 Human genes 0.000 description 1
102000005483 Cell Cycle Proteins Human genes 0.000 description 1
108010031896 Cell Cycle Proteins Proteins 0.000 description 1
206010008342 Cervix carcinoma Diseases 0.000 description 1
208000010833 Chronic myeloid leukaemia Diseases 0.000 description 1
102000041075 Class I family Human genes 0.000 description 1
108091060777 Class I family Proteins 0.000 description 1
201000002847 Cowden syndrome Diseases 0.000 description 1
102000008130 Cyclic AMP-Dependent Protein Kinases Human genes 0.000 description 1
108010049894 Cyclic AMP-Dependent Protein Kinases Proteins 0.000 description 1
102000004654 Cyclic GMP-Dependent Protein Kinases Human genes 0.000 description 1
108010003591 Cyclic GMP-Dependent Protein Kinases Proteins 0.000 description 1
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
238000000018 DNA microarray Methods 0.000 description 1
RWSOTUBLDIXVET-UHFFFAOYSA-N Dihydrogen sulfide Chemical compound S RWSOTUBLDIXVET-UHFFFAOYSA-N 0.000 description 1
102100031480 Dual specificity mitogen-activated protein kinase kinase 1 Human genes 0.000 description 1
101710146526 Dual specificity mitogen-activated protein kinase kinase 1 Proteins 0.000 description 1
102100023266 Dual specificity mitogen-activated protein kinase kinase 2 Human genes 0.000 description 1
101710146529 Dual specificity mitogen-activated protein kinase kinase 2 Proteins 0.000 description 1
102000054300 EC 2.7.11.- Human genes 0.000 description 1
108700035490 EC 2.7.11.- Proteins 0.000 description 1
102000001301 EGF receptor Human genes 0.000 description 1
108060006698 EGF receptor Proteins 0.000 description 1
238000002965 ELISA Methods 0.000 description 1
206010014733 Endometrial cancer Diseases 0.000 description 1
206010014759 Endometrial neoplasm Diseases 0.000 description 1
206010014967 Ependymoma Diseases 0.000 description 1
208000031637 Erythroblastic Acute Leukemia Diseases 0.000 description 1
208000036566 Erythroleukaemia Diseases 0.000 description 1
208000000461 Esophageal Neoplasms Diseases 0.000 description 1
208000006168 Ewing Sarcoma Diseases 0.000 description 1
206010064571 Gene mutation Diseases 0.000 description 1
201000010915 Glioblastoma multiforme Diseases 0.000 description 1
102000009465 Growth Factor Receptors Human genes 0.000 description 1
108010009202 Growth Factor Receptors Proteins 0.000 description 1
SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 description 1
101000600756 Homo sapiens 3-phosphoinositide-dependent protein kinase 1 Proteins 0.000 description 1
101001117146 Homo sapiens [Pyruvate dehydrogenase (acetyl-transferring)] kinase isozyme 1, mitochondrial Proteins 0.000 description 1
208000005726 Inflammatory Breast Neoplasms Diseases 0.000 description 1
206010021980 Inflammatory carcinoma of the breast Diseases 0.000 description 1
102000003746 Insulin Receptor Human genes 0.000 description 1
108010001127 Insulin Receptor Proteins 0.000 description 1
208000008839 Kidney Neoplasms Diseases 0.000 description 1
101150105104 Kras gene Proteins 0.000 description 1
AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 1
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
235000010643 Leucaena leucocephala Nutrition 0.000 description 1
240000007472 Leucaena leucocephala Species 0.000 description 1
208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 description 1
229930195725 Mannitol Natural products 0.000 description 1
102000008135 Mechanistic Target of Rapamycin Complex 1 Human genes 0.000 description 1
108010035196 Mechanistic Target of Rapamycin Complex 1 Proteins 0.000 description 1
208000000172 Medulloblastoma Diseases 0.000 description 1
208000035490 Megakaryoblastic Acute Leukemia Diseases 0.000 description 1
206010027406 Mesothelioma Diseases 0.000 description 1
241001465754 Metazoa Species 0.000 description 1
108700027649 Mitogen-Activated Protein Kinase 3 Proteins 0.000 description 1
102100024193 Mitogen-activated protein kinase 1 Human genes 0.000 description 1
108700015928 Mitogen-activated protein kinase 13 Proteins 0.000 description 1
102100024192 Mitogen-activated protein kinase 3 Human genes 0.000 description 1
208000003445 Mouth Neoplasms Diseases 0.000 description 1
208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 description 1
208000033776 Myeloid Acute Leukemia Diseases 0.000 description 1
208000001894 Nasopharyngeal Neoplasms Diseases 0.000 description 1
206010061306 Nasopharyngeal cancer Diseases 0.000 description 1
206010061309 Neoplasm progression Diseases 0.000 description 1
206010029260 Neuroblastoma Diseases 0.000 description 1
208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 1
238000000636 Northern blotting Methods 0.000 description 1
206010030155 Oesophageal carcinoma Diseases 0.000 description 1
108091008606 PDGF receptors Proteins 0.000 description 1
102000038030 PI3Ks Human genes 0.000 description 1
229910019142 PO4 Inorganic materials 0.000 description 1
235000019483 Peanut oil Nutrition 0.000 description 1
101710093328 Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform Proteins 0.000 description 1
101150063858 Pik3ca gene Proteins 0.000 description 1
208000007452 Plasmacytoma Diseases 0.000 description 1
102000011653 Platelet-Derived Growth Factor Receptors Human genes 0.000 description 1
102000010995 Pleckstrin homology domains Human genes 0.000 description 1
108050001185 Pleckstrin homology domains Proteins 0.000 description 1
208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 1
102000001708 Protein Isoforms Human genes 0.000 description 1
108010029485 Protein Isoforms Proteins 0.000 description 1
201000004681 Psoriasis Diseases 0.000 description 1
102100022122 Ras-related C3 botulinum toxin substrate 1 Human genes 0.000 description 1
206010038389 Renal cancer Diseases 0.000 description 1
208000004337 Salivary Gland Neoplasms Diseases 0.000 description 1
206010061934 Salivary gland cancer Diseases 0.000 description 1
206010039491 Sarcoma Diseases 0.000 description 1
206010040070 Septic Shock Diseases 0.000 description 1
MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
238000002105 Southern blotting Methods 0.000 description 1
208000005718 Stomach Neoplasms Diseases 0.000 description 1
206010042971 T-cell lymphoma Diseases 0.000 description 1
208000027585 T-cell non-Hodgkin lymphoma Diseases 0.000 description 1
208000024313 Testicular Neoplasms Diseases 0.000 description 1
206010057644 Testis cancer Diseases 0.000 description 1
AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
239000004473 Threonine Substances 0.000 description 1
208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
206010047741 Vulval cancer Diseases 0.000 description 1
208000004354 Vulvar Neoplasms Diseases 0.000 description 1
208000008383 Wilms tumor Diseases 0.000 description 1
230000009471 action Effects 0.000 description 1
208000021841 acute erythroid leukemia Diseases 0.000 description 1
208000013593 acute megakaryoblastic leukemia Diseases 0.000 description 1
208000020700 acute megakaryocytic leukemia Diseases 0.000 description 1
239000008272 agar Substances 0.000 description 1
235000010419 agar Nutrition 0.000 description 1
125000000539 amino acid group Chemical group 0.000 description 1
150000001413 amino acids Chemical class 0.000 description 1
239000003708 ampul Substances 0.000 description 1
238000004873 anchoring Methods 0.000 description 1
230000001028 anti-proliverative effect Effects 0.000 description 1
238000003782 apoptosis assay Methods 0.000 description 1
239000002585 base Substances 0.000 description 1
230000004071 biological effect Effects 0.000 description 1
201000011143 bone giant cell tumor Diseases 0.000 description 1
229910052791 calcium Inorganic materials 0.000 description 1
239000011575 calcium Substances 0.000 description 1
PASHVRUKOFIRIK-UHFFFAOYSA-L calcium sulfate dihydrate Chemical compound O.O.[Ca+2].[O-]S([O-])(=O)=O PASHVRUKOFIRIK-UHFFFAOYSA-L 0.000 description 1
108010025267 calcium-dependent protein kinase Proteins 0.000 description 1
235000014633 carbohydrates Nutrition 0.000 description 1
150000001720 carbohydrates Chemical class 0.000 description 1
239000003183 carcinogenic agent Substances 0.000 description 1
201000011529 cardiovascular cancer Diseases 0.000 description 1
230000003197 catalytic effect Effects 0.000 description 1
108010051348 cdc42 GTP-Binding Protein Proteins 0.000 description 1
230000022131 cell cycle Effects 0.000 description 1
230000024245 cell differentiation Effects 0.000 description 1
230000003915 cell function Effects 0.000 description 1
238000000006 cell growth inhibition assay Methods 0.000 description 1
210000000170 cell membrane Anatomy 0.000 description 1
230000009087 cell motility Effects 0.000 description 1
230000009134 cell regulation Effects 0.000 description 1
230000003833 cell viability Effects 0.000 description 1
230000033077 cellular process Effects 0.000 description 1
230000036755 cellular response Effects 0.000 description 1
230000005754 cellular signaling Effects 0.000 description 1
201000010881 cervical cancer Diseases 0.000 description 1
230000001684 chronic effect Effects 0.000 description 1
208000032852 chronic lymphocytic leukemia Diseases 0.000 description 1
239000004927 clay Substances 0.000 description 1
238000011260 co-administration Methods 0.000 description 1
210000001072 colon Anatomy 0.000 description 1
239000003086 colorant Substances 0.000 description 1
238000002648 combination therapy Methods 0.000 description 1
238000012790 confirmation Methods 0.000 description 1
238000003360 curve fit method Methods 0.000 description 1
231100000433 cytotoxic Toxicity 0.000 description 1
230000001472 cytotoxic effect Effects 0.000 description 1
231100000135 cytotoxicity Toxicity 0.000 description 1
230000003013 cytotoxicity Effects 0.000 description 1
230000006378 damage Effects 0.000 description 1
230000002939 deleterious effect Effects 0.000 description 1
230000001419 dependent effect Effects 0.000 description 1
238000013461 design Methods 0.000 description 1
238000001514 detection method Methods 0.000 description 1
238000003745 diagnosis Methods 0.000 description 1
230000004069 differentiation Effects 0.000 description 1
238000003113 dilution method Methods 0.000 description 1
239000002270 dispersing agent Substances 0.000 description 1
238000009510 drug design Methods 0.000 description 1
238000003255 drug test Methods 0.000 description 1
230000002900 effect on cell Effects 0.000 description 1
230000013020 embryo development Effects 0.000 description 1
239000000839 emulsion Substances 0.000 description 1
239000002532 enzyme inhibitor Substances 0.000 description 1
201000004101 esophageal cancer Diseases 0.000 description 1
238000011156 evaluation Methods 0.000 description 1
230000035558 fertility Effects 0.000 description 1
239000012894 fetal calf serum Substances 0.000 description 1
201000003444 follicular lymphoma Diseases 0.000 description 1
239000012634 fragment Substances 0.000 description 1
206010017758 gastric cancer Diseases 0.000 description 1
230000014509 gene expression Effects 0.000 description 1
ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
229940074045 glyceryl distearate Drugs 0.000 description 1
229940075507 glyceryl monostearate Drugs 0.000 description 1
239000003102 growth factor Substances 0.000 description 1
239000000122 growth hormone Substances 0.000 description 1
201000009277 hairy cell leukemia Diseases 0.000 description 1
206010073071 hepatocellular carcinoma Diseases 0.000 description 1
231100000844 hepatocellular carcinoma Toxicity 0.000 description 1
229940088597 hormone Drugs 0.000 description 1
125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
230000003463 hyperproliferative effect Effects 0.000 description 1
210000000987 immune system Anatomy 0.000 description 1
238000003365 immunocytochemistry Methods 0.000 description 1
230000006872 improvement Effects 0.000 description 1
238000011534 incubation Methods 0.000 description 1
201000004653 inflammatory breast carcinoma Diseases 0.000 description 1
239000007972 injectable composition Substances 0.000 description 1
229940102223 injectable solution Drugs 0.000 description 1
CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 1
229960000367 inositol Drugs 0.000 description 1
230000010354 integration Effects 0.000 description 1
230000003993 interaction Effects 0.000 description 1
230000002452 interceptive effect Effects 0.000 description 1
238000007918 intramuscular administration Methods 0.000 description 1
238000007913 intrathecal administration Methods 0.000 description 1
238000001990 intravenous administration Methods 0.000 description 1
ZLVXBBHTMQJRSX-VMGNSXQWSA-N jdtic Chemical compound C1([C@]2(C)CCN(C[C@@H]2C)C[C@H](C(C)C)NC(=O)[C@@H]2NCC3=CC(O)=CC=C3C2)=CC=CC(O)=C1 ZLVXBBHTMQJRSX-VMGNSXQWSA-N 0.000 description 1
201000010982 kidney cancer Diseases 0.000 description 1
239000008101 lactose Substances 0.000 description 1
238000012417 linear regression Methods 0.000 description 1
208000012987 lip and oral cavity carcinoma Diseases 0.000 description 1
150000002632 lipids Chemical class 0.000 description 1
239000006194 liquid suspension Substances 0.000 description 1
239000011777 magnesium Substances 0.000 description 1
235000019359 magnesium stearate Nutrition 0.000 description 1
230000036210 malignancy Effects 0.000 description 1
230000003211 malignant effect Effects 0.000 description 1
239000000594 mannitol Substances 0.000 description 1
235000010355 mannitol Nutrition 0.000 description 1
239000000463 material Substances 0.000 description 1
230000003340 mental effect Effects 0.000 description 1
108020004999 messenger RNA Proteins 0.000 description 1
230000004060 metabolic process Effects 0.000 description 1
230000000869 mutational effect Effects 0.000 description 1
239000013642 negative control Substances 0.000 description 1
230000017095 negative regulation of cell growth Effects 0.000 description 1
201000008026 nephroblastoma Diseases 0.000 description 1
210000000653 nervous system Anatomy 0.000 description 1
230000004770 neurodegeneration Effects 0.000 description 1
208000015122 neurodegenerative disease Diseases 0.000 description 1
210000000440 neutrophil Anatomy 0.000 description 1
231100000252 nontoxic Toxicity 0.000 description 1
230000003000 nontoxic effect Effects 0.000 description 1
239000002773 nucleotide Substances 0.000 description 1
125000003729 nucleotide group Chemical group 0.000 description 1
239000004006 olive oil Substances 0.000 description 1
235000008390 olive oil Nutrition 0.000 description 1
201000008968 osteosarcoma Diseases 0.000 description 1
201000004228 ovarian endometrial cancer Diseases 0.000 description 1
230000008506 pathogenesis Effects 0.000 description 1
238000010827 pathological analysis Methods 0.000 description 1
230000001575 pathological effect Effects 0.000 description 1
239000000312 peanut oil Substances 0.000 description 1
239000001814 pectin Substances 0.000 description 1
235000010987 pectin Nutrition 0.000 description 1
229920001277 pectin Polymers 0.000 description 1
230000000737 periodic effect Effects 0.000 description 1
239000008177 pharmaceutical agent Substances 0.000 description 1
239000000825 pharmaceutical preparation Substances 0.000 description 1
239000010452 phosphate Substances 0.000 description 1
150000003904 phospholipids Chemical class 0.000 description 1
230000035479 physiological effects, processes and functions Effects 0.000 description 1
239000002574 poison Substances 0.000 description 1
231100000614 poison Toxicity 0.000 description 1
238000006116 polymerization reaction Methods 0.000 description 1
102000054765 polymorphisms of proteins Human genes 0.000 description 1
239000013641 positive control Substances 0.000 description 1
239000000843 powder Substances 0.000 description 1
239000003755 preservative agent Substances 0.000 description 1
230000005522 programmed cell death Effects 0.000 description 1
210000004765 promyelocyte Anatomy 0.000 description 1
230000000069 prophylactic effect Effects 0.000 description 1
201000002025 prostate sarcoma Diseases 0.000 description 1
108010062302 rac1 GTP Binding Protein Proteins 0.000 description 1
230000025915 regulation of apoptotic process Effects 0.000 description 1
230000022532 regulation of transcription, DNA-dependent Effects 0.000 description 1
230000002441 reversible effect Effects 0.000 description 1
201000009410 rhabdomyosarcoma Diseases 0.000 description 1
206010039073 rheumatoid arthritis Diseases 0.000 description 1
CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 1
230000036303 septic shock Effects 0.000 description 1
238000012163 sequencing technique Methods 0.000 description 1
238000013207 serial dilution Methods 0.000 description 1
230000011664 signaling Effects 0.000 description 1
230000007781 signaling event Effects 0.000 description 1
238000009097 single-agent therapy Methods 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
235000002639 sodium chloride Nutrition 0.000 description 1
229940054269 sodium pyruvate Drugs 0.000 description 1
230000037439 somatic mutation Effects 0.000 description 1
201000011549 stomach cancer Diseases 0.000 description 1
238000007920 subcutaneous administration Methods 0.000 description 1
239000000126 substance Substances 0.000 description 1
238000006467 substitution reaction Methods 0.000 description 1
238000013268 sustained release Methods 0.000 description 1
239000012730 sustained-release form Substances 0.000 description 1
208000024891 symptom Diseases 0.000 description 1
230000007761 synergistic anti-cancer Effects 0.000 description 1
230000009897 systematic effect Effects 0.000 description 1
201000003120 testicular cancer Diseases 0.000 description 1
229940124597 therapeutic agent Drugs 0.000 description 1
238000011287 therapeutic dose Methods 0.000 description 1
230000000699 topical effect Effects 0.000 description 1
231100000331 toxic Toxicity 0.000 description 1
230000002588 toxic effect Effects 0.000 description 1
231100000419 toxicity Toxicity 0.000 description 1
230000001988 toxicity Effects 0.000 description 1
206010044412 transitional cell carcinoma Diseases 0.000 description 1
102000035160 transmembrane proteins Human genes 0.000 description 1
108091005703 transmembrane proteins Proteins 0.000 description 1
230000005751 tumor progression Effects 0.000 description 1
201000005112 urinary bladder cancer Diseases 0.000 description 1
239000003981 vehicle Substances 0.000 description 1
201000005102 vulva cancer Diseases 0.000 description 1
239000001993 wax Substances 0.000 description 1
238000001262 western blot Methods 0.000 description 1

Images

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
- A61K31/51—Thiamines, e.g. vitamin B1
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
General Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Epidemiology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Endocrinology (AREA)
Reproductive Health (AREA)
Dermatology (AREA)
Pulmonology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

JP2012534272A 2009-10-12 2010-10-12 組合せ Ceased JP2013507442A (ja)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US25063509P	2009-10-12	2009-10-12
US61/250,635		2009-10-12
PCT/US2010/052242 WO2011046894A1 (en)	2009-10-12	2010-10-12	Combination

Publications (2)

Publication Number	Publication Date
JP2013507442A true JP2013507442A (ja)	2013-03-04
JP2013507442A5 JP2013507442A5 (2)	2013-10-24

Family

ID=43876468

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
JP2012534272A Ceased JP2013507442A (ja)	2009-10-12	2010-10-12	組合せ

Country Status (13)

Country	Link
US (1)	US20120202822A1 (2)
EP (1)	EP2488184A4 (2)
JP (1)	JP2013507442A (2)
KR (1)	KR20120097496A (2)
CN (1)	CN102665720A (2)
AU (1)	AU2010307043C1 (2)
BR (1)	BR112012008519A2 (2)
CA (1)	CA2777561A1 (2)
EA (1)	EA020965B1 (2)
IL (1)	IL219103A0 (2)
MX (1)	MX2012004259A (2)
WO (1)	WO2011046894A1 (2)
ZA (1)	ZA201202416B (2)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP2013545756A (ja) *	2010-11-16	2013-12-26	グラクソスミスクライン、インテレクチュアル、プロパティー、ナンバー２、リミテッド	投与および治療方法
JP6342396B2 (ja)	2012-08-07	2018-06-13	ノバルティスアーゲー	Ｂ−Ｒａｆ阻害薬、ＥＧＦＲ阻害薬及び場合によってはＰＩ３Ｋ−α阻害薬を含む組合せ医薬
KR20190057421A (ko)	2012-08-17	2019-05-28	에프. 호프만-라 로슈 아게	코비메티닙 및 베무라피닙을 투여함을 포함하는 흑색종의 조합 치료법
CN103936728B (zh) *	2013-01-18	2016-08-10	通化济达医药有限公司	噻唑激酶抑制剂
CN103936730A (zh) *	2013-01-22	2014-07-23	通化济达医药有限公司	苯磺酰胺噻唑激酶抑制剂
CN103965180B (zh) *	2013-01-24	2016-09-07	通化济达医药有限公司	苯磺酰胺噁唑和噻唑激酶抑制剂
US20150352121A1 (en) *	2013-03-12	2015-12-10	Glaxosmithkline Llc	Combination
MA38522A1 (fr)	2013-03-21	2017-10-31	Novartis Ag	Thérapie de combinaison comprenant un inhibiteur de b-raf et un second inhibiteur.
WO2015003571A1 (zh) *	2013-07-08	2015-01-15	杭州普晒医药科技有限公司	达拉菲尼甲磺酸盐的新晶型及其制备方法
US11007183B2 (en) *	2013-12-20	2021-05-18	Biomed Valley Discoveries, Inc.	Cancer treatments using combinations of PI3K/Akt pathway and ERK inhibitors

Citations (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2008144463A1 (en) *	2007-05-18	2008-11-27	Smithkline Beecham Corporation	Quinoline derivatives as pi3 kinase inhibitors
WO2009137391A2 (en) *	2008-05-06	2009-11-12	Smithkline Beecham Corporation	Benzene sulfonamide thiazole and oxazole compounds

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA2349832A1 (en) *	1999-01-13	2000-07-20	Warner-Lambert Company	Benzenesulfonamide derivatives and their use as mek inhibitors
US8835473B2 (en) *	2004-04-16	2014-09-16	Rutgers, The State University Of New Jersey	Methods and compositions for treating cancer
US7691377B2 (en) *	2004-04-16	2010-04-06	Rutgers, The State University Of New Jersey	Methods and compositions for treating melanoma
WO2007084391A2 (en) *	2006-01-18	2007-07-26	Amgen Inc.	Thiazole compounds as protein kinase b ( pkb) inhibitors

2010
- 2010-10-12 EP EP20100823916 patent/EP2488184A4/en not_active Withdrawn
- 2010-10-12 MX MX2012004259A patent/MX2012004259A/es active IP Right Grant
- 2010-10-12 KR KR1020127011760A patent/KR20120097496A/ko not_active Withdrawn
- 2010-10-12 US US13/501,387 patent/US20120202822A1/en not_active Abandoned
- 2010-10-12 CN CN2010800564396A patent/CN102665720A/zh active Pending
- 2010-10-12 JP JP2012534272A patent/JP2013507442A/ja not_active Ceased
- 2010-10-12 WO PCT/US2010/052242 patent/WO2011046894A1/en not_active Ceased
- 2010-10-12 BR BR112012008519A patent/BR112012008519A2/pt not_active IP Right Cessation
- 2010-10-12 CA CA2777561A patent/CA2777561A1/en not_active Abandoned
- 2010-10-12 EA EA201270537A patent/EA020965B1/ru not_active IP Right Cessation
- 2010-10-12 AU AU2010307043A patent/AU2010307043C1/en not_active Ceased
2012
- 2012-04-03 ZA ZA2012/02416A patent/ZA201202416B/en unknown
- 2012-04-05 IL IL219103A patent/IL219103A0/en unknown

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2008144463A1 (en) *	2007-05-18	2008-11-27	Smithkline Beecham Corporation	Quinoline derivatives as pi3 kinase inhibitors
WO2009137391A2 (en) *	2008-05-06	2009-11-12	Smithkline Beecham Corporation	Benzene sulfonamide thiazole and oxazole compounds

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
JPN6014039050; Ｊ．　Ｇ．　Ｓｈｅｌｔｏｎ　ｅｔ　ａｌ．: Ｏｎｃｏｇｅｎｅｖｏｌ．２２, 2003, ｐ．２４７８-２４９２ *
JPN6014039051; Ｌ．　Ａ．　Ｅｄｗａｒｄｓ　ｅｔ　ａｌ．: Ｍｏｌ．　Ｃａｎｃｅｒ　Ｔｈｅｒ．ｖｏｌ．５，　Ｎｏ．３, 2006, ｐ．６４５-６５４ *
JPN6014039052; Ｏ．　Ｋ．　Ｍｉｒｚｏｅｖａ　ｅｔ　ａｌ．: Ｃａｎｃｅｒ　Ｒｅｓ．ｖｏｌ．６９，　Ｎｏ．２, 20090115, ｐ．５６５-５７２ *

Also Published As

Publication number	Publication date
ZA201202416B (en)	2012-12-27
EP2488184A1 (en)	2012-08-22
MX2012004259A (es)	2012-05-29
AU2010307043C1 (en)	2014-03-13
AU2010307043A1 (en)	2012-05-17
EP2488184A4 (en)	2013-04-24
IL219103A0 (en)	2012-06-28
EA201270537A1 (ru)	2012-12-28
CA2777561A1 (en)	2011-04-21
BR112012008519A2 (pt)	2016-04-05
CN102665720A (zh)	2012-09-12
KR20120097496A (ko)	2012-09-04
AU2010307043B2 (en)	2013-10-31
EA020965B1 (ru)	2015-03-31
US20120202822A1 (en)	2012-08-09
WO2011046894A1 (en)	2011-04-21

Legal Events

Date	Code	Title	Description
2013-09-06	A521	Request for written amendment filed	Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20130905
2013-09-06	A621	Written request for application examination	Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20130905
2014-09-16	A131	Notification of reasons for refusal	Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20140912
2014-12-13	A601	Written request for extension of time	Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20141212
2014-12-22	A602	Written permission of extension of time	Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20141219
2015-01-13	A521	Request for written amendment filed	Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20150113
2015-04-08	A01	Written decision to grant a patent or to grant a registration (utility model)	Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20150407
2015-08-24	A045	Written measure of dismissal of application [lapsed due to lack of payment]	Free format text: JAPANESE INTERMEDIATE CODE: A045 Effective date: 20150821

Publication	Publication Date	Title
JP2013507442A (ja)	2013-03-04	組合せ
JP6479812B2 (ja)	2019-03-06	細胞増殖性疾患を治療するためのａｌｋ阻害剤とｃｄｋ阻害剤との組合せ
KR20180041677A (ko)	2018-04-24	Mdm2 억제제 및 그의 조합물
MX2013009351A (es)	2014-01-08	Terapia de combinacion de inhibidor de objetivo de rapamicina en mamifero/janus cinasa (mtor/jak).
TW202031253A (zh)	2020-09-01	治療黑色素瘤的藥物組合
KR20140072028A (ko)	2014-06-12	Pi3k- 및 mek-억제제의 상승작용적 조합물
JP2016106092A (ja)	2016-06-16	組合せ
KR20160090814A (ko)	2016-08-01	Jak, cdk 및 pim의 억제제를 포함하는 조합 요법
KR20150067323A (ko)	2015-06-17	조합물
KR20120100978A (ko)	2012-09-12	조합물
KR101696003B1 (ko)	2017-01-13	조합물
JP2021529177A (ja)	2021-10-28	ポジオチニブと細胞毒性剤および／またはその他の分子標的化薬剤との組合せならびにその使用
JP6148320B2 (ja)	2017-06-14	組合せ
JP2013505962A (ja)	2013-02-21	組合せ